Progesterone as Luteal Support in Frozen IVF Natural Cycles

Launched by VASTRA GOTALAND REGION · Jan 21, 2021

Keywords

ClinConnect Summary

The ProFET study is a clinical trial that looks at how vaginal progesterone, a hormone, can help support women during the luteal phase of their menstrual cycle after having a frozen embryo transfer (FET) following in-vitro fertilization (IVF). The researchers want to find out if using progesterone can lead to a higher chance of having a live birth compared to not using it at all, and whether treating for 7 weeks is more effective than treating for just 3 weeks.

To participate in this study, women must be planning for a frozen embryo transfer with a specific type of embryo called a blastocyst, have a body mass index (BMI) between 18.5 and 35, and have regular menstrual cycles. Participants need to understand either Swedish, English, or Arabic, and they must provide informed consent. The study is currently recruiting participants, and those who join can expect to receive either the progesterone treatment or no treatment at all while being closely monitored throughout the process. It's important to note that certain medical conditions or previous participation in other studies may exclude some women from joining this trial.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • Planned for a FET-NC with a blastocyst
• • BMI \>18.5 \<35
• • Regular menstrual cycles 24-35 days
• • Given informed consent
• • Understand written and spoken Swedish, English or Arabic
• Exclusion Criteria:
• • Oocyte donor cycles, preimplantation genetic testing (PGT) cycles. Uterine malformation, submucous myoma and endometrial polyps.
• • Hypersensitivity against study medication. Other contraindications according to www.fass.se
• • Development of serious disease contraindicating ART or pregnancy.
• • Participation or recent participation in a clinical study with an investigational product (past 30 days). Previous participation in this study.